Japan Genetic Testing Market Report 2026

Market Size in 2025: USD 651.9 Million

Market Forecast in 2034: USD 4,109.2 Million

Market Growth Rate: 22.70% (2026-2034)

According to the latest report by IMARC Group, titled “Japan Genetic Testing Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034," the Japan genetic testing market size reached USD 651.9 Million in 2025. Looking forward, the market is expected to reach USD 4,109.2 Million by 2034, exhibiting a CAGR of 22.70% during the forecast period from 2026 to 2034.

Download a Free Sample Report: https://www.imarcgroup.com/japan-genetic-testing-market/requestsample

Japan Genetic Testing Market Trends & Drivers

The Japan Genetic Testing Market is expanding quickly in 2026 as healthcare providers and patients make greater use of genetic insights in clinical decisions. Testing is used to assess inherited disease risk, determine carrier status, support prenatal and newborn screening, and guide personalized treatment, with cancer and hereditary conditions drawing the most clinical attention. An ageing population is increasing the burden of genetic and hereditary diseases, which raises demand for diagnostic and predictive testing. Japan’s emphasis on precision medicine is also encouraging physicians to match therapies to a patient’s genetic profile, and pharmacogenomic testing is gaining relevance as treatment choices become more individualized. Insurance coverage for selected genetic tests is further improving access in clinical settings.

Scientific progress and national coordination are strengthening the second layer of growth. Biotechnology research has produced more advanced testing techniques, particularly in DNA sequencing, widening applications from disease risk assessment to drug response analysis. Rising awareness of personalized medicine is drawing consumers toward ancestry and health-risk testing, while investment in research and healthcare infrastructure supports laboratory capacity. In 2026, a new national body was established to coordinate how whole-genome sequencing data is collected and shared across research institutions, companies, and clinicians. Such efforts are expected to improve data availability, accelerate drug discovery, and support the long-term expansion of testing services in Japan.

How AI is Reshaping the Future of the Japan Genetic Testing Market

• Variant Interpretation and Genomic Data Analysis: Artificial intelligence analyzes large sequencing datasets to identify and classify genetic variants. Machine learning models flag clinically relevant mutations faster than manual review. Predictive systems reduce turnaround time for laboratory reports.
• Cancer Diagnosis and Risk Prediction: AI-powered systems combine genomic profiles with clinical records to estimate disease risk. Machine learning algorithms support tumor profiling and treatment matching. Predictive analytics assist physicians in selecting therapies suited to individual patients.
• Drug Discovery and Pharmacogenomics: Artificial intelligence links genetic variation to drug response and adverse reaction risk. Machine learning models help researchers identify new targets in genomic databases. Predictive tools support personalized dosing and treatment decisions.

Japan Genetic Testing Market Segmentation

The market report offers a comprehensive analysis of the segments, highlighting those with the largest Japan genetic testing market share. It includes forecasts for the period 2026-2034 and historical data from 2020-2025 for the following segments.

Type Insights:

• Predictive and Presymptomatic Testing
• Carrier Testing
• Prenatal and Newborn Testing
• Diagnostic Testing
• Pharmacogenomic Testing
• Others

The report has provided a detailed breakup and analysis of the market based on the type. This includes predictive and presymptomatic testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and others.

Technology Insights:

• Cytogenetic Testing and Chromosome Analysis
• Biochemical Testing
• Molecular Testing
  • DNA Sequencing
  • Others

A detailed breakup and analysis of the market based on the technology has also been provided in the report. This includes cytogenetic testing and chromosome analysis, biochemical testing, and molecular testing (DNA sequencing and others).

Application Insights:

• Cancer Diagnosis
• Genetic Disease Diagnosis
• Cardiovascular Disease Diagnosis
• Others

A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others.

Regional Insights:

• Kanto Region
• Kansai/Kinki Region
• Central/Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region

Request a Customized Version of This Report for Deeper Insights: https://www.imarcgroup.com/request?type=report&id=16295&flag=E

Competitive Landscape

Key Players:

• Sysmex Corporation
• Genesis Healthcare Co.
• RIKEN GENESIS Co., Ltd.
• GeneLife

Recent News and Developments in Japan Genetic Testing Market

• July 2026: Sysmex’s PrismGuide APOE Genotyping Kit received the first insurance coverage in Japan for assessing the risk of adverse reactions to anti-amyloid β antibody drugs used in Alzheimer’s treatment, with coverage effective July 1, 2026.
• April 2026: Japan launched the Japan Genome Medical Promotion Organization (GeMJ) to build a centralized database combining whole-genome sequencing results with clinical information for patients with cancer and intractable diseases.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

Street: 563-13 Kamien
Country: Tokyo, Japan
Postal Code: 4380111
Email: sales@imarcgroup.com

Source: IMARC Group